Cargando…

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment

The effect of moderate hepatic impairment on the pharmacokinetics (PK), safety, and tolerability of the dual endothelin receptor antagonist aprocitentan was clinically investigated as 25% of aprocitentan is cleared through the liver. Aprocitentan is in clinical development for the treatment of resis...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fontes, Magda S. C., Dingemanse, Jasper, Halabi, Atef, Tomaszewska-Kiecana, Monika, Sidharta, Patricia N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645340/ https://www.ncbi.nlm.nih.gov/pubmed/36352054 http://dx.doi.org/10.1038/s41598-022-22470-z

Ejemplares similares

Single- and multiple-dose tolerability, safety, pharmacokinetics, and pharmacodynamics of the dual endothelin receptor antagonist aprocitentan in healthy adult and elderly subjects
por: Sidharta, Patricia N, et al.
Publicado: (2019)

Effects of the Dual Endothelin Receptor Antagonist Aprocitentan on Body Weight and Fluid Homeostasis in Healthy Subjects on a High Sodium Diet
por: Gueneau de Mussy, Pierre, et al.
Publicado: (2020)

Macitentan: entry-into-humans study with a new endothelin receptor antagonist
por: Sidharta, Patricia N., et al.
Publicado: (2011)

Clinical Pharmacokinetics and Pharmacodynamics of the Endothelin Receptor Antagonist Macitentan
por: Sidharta, P. N., et al.
Publicado: (2015)

Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension
por: Verweij, Pierre, et al.
Publicado: (2020)

Aprocitentan, A Dual Endothelin Receptor Antagonist Under Development for the Treatment of Resistant Hypertension
por: Angeli, Fabio, et al.
Publicado: (2021)

Effect of Cyclosporine and Rifampin on the Pharmacokinetics of Macitentan, a Tissue-Targeting Dual Endothelin Receptor Antagonist
por: Bruderer, Shirin, et al.
Publicado: (2011)

Dual Endothelin Antagonism with Aprocitentan as a Novel Therapeutic Approach for Resistant Hypertension
por: Heidari Nejad, Sayeh, et al.
Publicado: (2023)

Influence of hepatic impairment on the pharmacokinetics and pharmacodynamics of the P2Y12 receptor antagonist selatogrel
por: Schilling, Uta, et al.
Publicado: (2022)

Aprocitentan: New insights
por: Varzideh, Fahimeh, et al.
Publicado: (2022)

Pharmacokinetics of daridorexant, a dual orexin receptor antagonist, are not affected by renal impairment
por: Berger, Benjamin, et al.
Publicado: (2021)

Population pharmacokinetic modeling of daridorexant, a novel dual orexin receptor antagonist
por: Krause, Andreas, et al.
Publicado: (2022)

Aprocitentan: A new development of resistant hypertension
por: Yao, Yao, et al.
Publicado: (2023)

Clinical Pharmacology of Clazosentan, a Selective Endothelin A Receptor Antagonist for the Prevention and Treatment of aSAH-Related Cerebral Vasospasm
por: Juif, Pierre-Eric, et al.
Publicado: (2021)

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment
por: Schnell, David, et al.
Publicado: (2014)

Absence of Pharmacokinetic and Pharmacodynamic Interactions between Almorexant and Warfarin in Healthy Subjects
por: Dingemanse, Jasper, et al.
Publicado: (2013)

Endothelin and Endothelin Antagonists in Chronic Kidney Disease
por: Kohan, Donald E., et al.
Publicado: (2014)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P(1) Receptor Modulator in Healthy Subjects
por: Juif, Pierre-Eric, et al.
Publicado: (2017)

The effect of the glucosylceramide synthase inhibitor lucerastat on cardiac repolarization: results from a thorough QT study in healthy subjects
por: Mueller, Markus S., et al.
Publicado: (2020)

Lucerastat, an iminosugar with potential as substrate reduction therapy for glycolipid storage disorders: safety, tolerability, and pharmacokinetics in healthy subjects
por: Guérard, N., et al.
Publicado: (2017)

Identifying and treating resistant hypertension in PRECISION: A randomized long‐term clinical trial with aprocitentan
por: Danaietash, Parisa, et al.
Publicado: (2022)

Pharmacokinetics and Tolerability of the Novel Oral Prostacyclin IP Receptor Agonist Selexipag
por: Kaufmann, Priska, et al.
Publicado: (2015)

Pharmacokinetic/pharmacodynamic modeling of drug interactions at the P2Y(12) receptor between selatogrel and oral P2Y(12) antagonists
por: Henrich, Andrea, et al.
Publicado: (2021)

Absorption, Metabolism, and Excretion of ACT-1004-1239, a First-In-Class CXCR7 Antagonist: In Vitro, Preclinical, and Clinical Data
por: Huynh, Christine, et al.
Publicado: (2022)

The Role of Endothelin-1 and Endothelin Receptor Antagonists in Inflammatory Response and Sepsis
por: Kowalczyk, Agata, et al.
Publicado: (2014)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

Pharmacokinetics and Pharmacodynamics of Cenerimod, A Selective S1P(1)R Modulator, Are Not Affected by Ethnicity in Healthy Asian and White Subjects
por: Juif, Pierre‐Eric, et al.
Publicado: (2020)

First‐in‐human study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALPN‐101, a dual CD28/ICOS antagonist, in healthy adult subjects
por: Yang, Jing, et al.
Publicado: (2021)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Antidiuretic Effects of the Endothelin Receptor Antagonist Avosentan
por: Baltatu, Ovidiu Constantin, et al.
Publicado: (2012)

Iontophoresis of Endothelin Receptor Antagonists in Rats and Men
por: Roustit, Matthieu, et al.
Publicado: (2012)

Endothelin antagonists in subarachnoid hemorrhage: what next?
por: Macdonald, R Loch
Publicado: (2012)

Evidence for biased agonists and antagonists at the endothelin receptors
por: Maguire, Janet J.
Publicado: (2016)

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function
por: Kunz, Christina, et al.
Publicado: (2016)

Pharmacokinetic/pharmacodynamic modelling of the antimalarial effect of Actelion‐451840 in an induced blood stage malaria study in healthy subjects
por: Krause, Andreas, et al.
Publicado: (2016)

Effect of Rifampin‐Mediated OATP1B1 and OATP1B3 Transporter Inhibition on the Pharmacokinetics of the P2Y12 Receptor Antagonist Selatogrel
por: Schilling, Uta, et al.
Publicado: (2020)

Endothelin antagonists: new bullets against lung injury?
por: Leeman, Marc
Publicado: (2005)

Safety, Tolerability and Pharmacokinetics of the Serotonin 5-HT6 Receptor Antagonist, HEC30654, in Healthy Chinese Subjects
por: Li, Xiaojiao, et al.
Publicado: (2021)

Assessment of Target Engagement in a First‐in‐Human Trial with Sinbaglustat, an Iminosugar to Treat Lysosomal Storage Disorders
por: Gehin, Martine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i72aqlc3a4aucvhb5063cc41oc